AMGEN INC (AMGN)
S&P 500DOW 30NASDAQ-100XNASBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)Net insider selling (90d)Watch AMGN
$0.00-$0.92 (-0.21%) TodayExtended Hours
Derek Miller - OfficerDerek Miller - OfficerAmgen is a leader in biotechnology-based human therapeutics. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drugs Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx Pharmaceuticals bolstered the firm's therapeutic oncology portfolio with Kyprolis, which has been further strengthened with the launch of new drugs in blood cancers (Blincyto) and solid tumors (Imdelltra). The 2023 Horizon acquisition brought several rare-disease drugs, including thyroid eye disease drug Tepezza. Amgen also has a growing biosimilar portfolio.
| Form 4 transaction type | Transactions | Shares | Total value |
|---|---|---|---|
| Open-market sale | 6 | 10,112 | $4.11M |
| Grant or award | 4 | 982.46 | |
| Option exercise | 10 | 16,224 |
Dollar totals are shown for open-market purchases and sales only. Grants, option exercises, gifts and tax withholding are reported by share count because they are not trades at a market price.
102 Form 4 filings on record, the earliest from Nov 6, 2024, newest first. Filing history page 3 of 3.
| Date | Insider | Transaction | Security | Shares | Price | Value |
|---|---|---|---|---|---|---|
| Murdo Gordon - Officer | Tax withholding / forfeiture | Common Stock | 6,691 | $366.21 | $2.45M | |
 Robert A. Bradway - Officer | Tax withholding / forfeiture | Common Stock | 21,294 | $366.21 | $7.80M | |
| Matthew C. Busch - Officer | Tax withholding / forfeiture | Common Stock | 327 | $366.21 | $120K | |
| Robert A. Bradway - Officer | Tax withholding / forfeiture | Common Stock | 84,285 | $379.27 | $31.97M | |
| Robert A. Bradway - Officer | Option exercise | Nqso (Right to Buy) | 119,782 | $0.00 | - | |
| Robert A. Bradway - Officer | Option exercise | Common Stock | 119,782 | $156.35 | $18.73M | |
 Esteban Santos - Officer | Grant or award | Common Stock | 11,259 | $0.00 | - | |
| David M. Reese - Officer | Grant or award | Common Stock | 12,063 | $0.00 | - | |
| Derek Miller - Officer | Grant or award | Common Stock | 3,484 | $0.00 | - | |
| Rachna Khosla - Officer | Grant or award | Common Stock | 1,876 | $0.00 | - | |
| Nancy A. Grygiel - Officer | Grant or award | Common Stock | 2,010 | $0.00 | - | |
 Peter H. Griffith - Officer | Grant or award | Common Stock | 12,063 | $0.00 | - | |
| Jonathan P. Graham - Officer | Grant or award | Common Stock | 10,723 | $0.00 | - | |
| Murdo Gordon - Officer | Grant or award | Common Stock | 13,403 | $0.00 | - | |
| Robert A. Bradway - Officer | Grant or award | Common Stock | 42,657 | $0.00 | - | |
| Matthew C. Busch - Officer | Grant or award | Common Stock | 938 | $0.00 | - | |
| Esteban Santos - Officer | Option exercise | Common Stock | 30,501 | $162.60 | $4.96M | |
| Esteban Santos - Officer | Option exercise | Common Stock | 24,291 | $177.46 | $4.31M | |
| Esteban Santos - Officer | Option exercise | Nqso (Right to Buy) | 30,501 | $0.00 | - | |
| Esteban Santos - Officer | Option exercise | Nqso (Right to Buy) | 24,291 | $0.00 | - | |
| Esteban Santos - Officer | Open-market sale | Common Stock | 30,501 | $379.12 | $11.56M | |
| Esteban Santos - Officer | Open-market sale | Common Stock | 24,291 | $379.12 | $9.21M | |
| Matthew C. Busch - Officer | Open-market sale | Common Stock | 1,000 | $375.79 | $376K | |
| James E. Bradner - Officer | Tax withholding / forfeiture | Common Stock | 2,151 | $384.32 | $827K | |
| James E. Bradner - Officer | Tax withholding / forfeiture | Common Stock | 953 | $384.32 | $366K | |
| Nancy A. Grygiel - Officer | Open-market sale | Common Stock | 1,639 | $337.26 | $553K | |
| Nancy A. Grygiel - Officer | Option exercise | Common Stock | 1,500 | $177.46 | $266K | |
| Nancy A. Grygiel - Officer | Option exercise | Common Stock | 1,639 | $162.60 | $267K | |
| Nancy A. Grygiel - Officer | Option exercise | Nqso (Right to Buy) | 1,500 | $0.00 | - | |
| Nancy A. Grygiel - Officer | Option exercise | Nqso (Right to Buy) | 1,639 | $0.00 | - | |
| Nancy A. Grygiel - Officer | Open-market sale | Common Stock | 1,500 | $337.26 | $506K | |
| Rachna Khosla - Officer | Open-market sale | Common Stock | 890 | $336.24 | $299K | |
| Murdo Gordon - Officer | Open-market sale | Common Stock | 6,879 | $336.83 | $2.32M | |
| Omar Ishrak - Director | Grant or award | Common Stock | 218.61 | $0.00 | - | |
| David M. Reese - Officer | Gift | Common Stock | 6,490 | $0.00 | - | |
| David M. Reese - Officer | Gift | Common Stock | 309 | $0.00 | - | |
 Charles M. Holley - Director | Grant or award | Common Stock | 265.46 | $0.00 | - | |
| Michael V. Drake - Director | Grant or award | Common Stock | 218.61 | $0.00 | - | |
| Rachna Khosla - Officer | Tax withholding / forfeiture | Common Stock | 226 | $296.70 | $67K | |
| Matthew C. Busch - Officer | Tax withholding / forfeiture | Common Stock | 202 | $296.70 | $60K | |
| Nancy A. Grygiel - Officer | Open-market sale | Common Stock | 1,267 | $296.99 | $376K | |
| Omar Ishrak - Director | Grant or award | Common Stock | 121.43 | $0.00 | - | |
| Charles M. Holley - Director | Grant or award | Common Stock | 147.45 | $0.00 | - | |
| Michael V. Drake - Director | Grant or award | Common Stock | 121.43 | $0.00 | - |
This is as far as the anonymous view goes. Create a free account for all 102 AMGN filings on record.
A Form 144 is notice of an INTENDED sale, not a completed one. It often precedes the Form 4 that reports the trade actually happening.
| Filed | Filer | Relationship | Shares | Market value | Notice |
|---|---|---|---|---|---|
| Khosla Rachna | Officer | 1,252 | $517K | View on EDGAR | |
| Khosla Rachna | Officer | 2,000 | $828K | View on EDGAR | |
| Derek Miller | Officer | 3,890 | $1.57M | View on EDGAR |
AMGEN INC (AMGN) had 7 insider filings in the last 90 days, with the most recent on 2026-08-13. The full record for AMGN runs to 102 Form 4 filings, the earliest from 2024-11-06. InsiderAlpha tracks every Form 4, Form 144, and 8-K filing in real time.
No insider purchases of AMGN were filed in the last 90 days.
6 insider sales of AMGN were filed in the last 90 days, totaling $4.11M.
This page tracks AMGN Form 4 insider transactions, Form 144 sale notices, and 8-K material event disclosures in one timeline. Annual 10-K and quarterly 10-Q reports live on the company's SEC EDGAR page.
Create a free InsiderAlpha account and press Watch on this page to add AMGN to your watchlist. A free account also opens the full scored daily plan with every past day and 3 months of price history. No card is required. Sign up at https://insideralpha.ai/register.
Every Form 4 below links to the original document on SEC EDGAR, so the numbers on this page can be checked against the filing they came from.
Real-time Form 4 alerts, AI-scored daily trade ideas and 10b5-1 plan flags.
